Growing community of inventors

New York, NY, United States of America

Esther Latres

Average Co-Inventor Count = 2.46

ph-index = 5

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 132

Esther LatresTrevor Stitt (7 patents)Esther LatresAndrew J Murphy (2 patents)Esther LatresGeorge D Yancopoulos (2 patents)Esther LatresJesper Gromada (2 patents)Esther LatresLori C Morton (2 patents)Esther LatresMichele Pagano (1 patent)Esther LatresDavid J Glass (1 patent)Esther LatresDah Shiarn Chiaur (1 patent)Esther LatresEsther Latres (10 patents)Trevor StittTrevor Stitt (8 patents)Andrew J MurphyAndrew J Murphy (349 patents)George D YancopoulosGeorge D Yancopoulos (200 patents)Jesper GromadaJesper Gromada (47 patents)Lori C MortonLori C Morton (16 patents)Michele PaganoMichele Pagano (14 patents)David J GlassDavid J Glass (14 patents)Dah Shiarn ChiaurDah Shiarn Chiaur (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Regeneron Pharmaceuticals, Inc. (9 from 1,343 patents)

2. New York University (1 from 1,627 patents)


10 patents:

1. 11655291 - Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A

2. 10526403 - Anti-activin A antibodies and uses thereof

3. 10400036 - Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A

4. 9890212 - Antibodies to human GDF8

5. 9718881 - Anti-Activin A antibodies and uses thereof

6. 9260515 - Antibodies to human GDF8

7. 8871209 - Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A

8. 8840894 - Antibodies to human GDF8

9. 7632503 - Method of treating a muscle-related condition with modified IGF1 polypeptides

10. 6720181 - Ubiquitin ligases as therapeutic targets

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/28/2025
Loading…